Clinical trial
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With…
NCT00075218 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00075218 |
|---|---|
| Title | A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug |
| Interventions | Placebo, SU011248 |
| Enrollment | 361 |
| Start date | Dec 1, 2003 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 8, 2004 |
| Last update posted | Sep 28, 2009 |
| Countries | Australia, Belgium, Canada, France, Italy, Netherlands, Singapore, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: